Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Senescence-Targeted Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDKN1A (P21) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDKN1A (P21) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or HEK293 expressed. |
View CDKN1A Products |
| Gene Delivery | CDKN1A Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression assays. |
View CDKN1A Products |
| Benchmark Ab | Anti-CDKN1A Recombinant Antibody Recombinant positive control for Western Blot, IHC, and Flow Cytometry. |
View CDKN1A Products |
| Validator | CDKN1A siRNA Set For target knockdown verification and pathway specificity assays. |
View CDKN1A Products |
| Related Target A | CDK2 Primary downstream kinase partner inhibited by CDKN1A during cell cycle arrest. |
View CDK2 Products |
| Related Target B | TP53 Upstream master transcriptional regulator of CDKN1A expression under cellular stress. |
View TP53 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular localization analysis (Nuclear vs. Cytoplasmic) | Sequence-verified wild-type and localization-mutant plasmids/lentiviruses available for cell-based imaging assays. |
| Protein-protein interaction (PPI) screening (CDK2/CDK4 binding) | High-purity, natively folded CDKN1A recombinant proteins with verified molecular weight and >95% purity. |
| Lack of reliable positive controls | Sequence-defined clinical-grade benchmark antibodies included in the portfolio. |
| Off-target assay signals | Sequence-specific validated siRNA pools included for target-specific knockdown controls. |
Live CDKN1A (P21) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the CDKN1A (P21) pathway is experiencing a significant resurgence. Long recognized as a downstream effector of the p53 tumor suppressor pathway, P21 is now emerging as a key node in two major therapeutic frontiers: oncology drug resistance and cellular senescence (senolytics). As first-generation CDK4/6 inhibitors encounter resistance in the clinic, next-generation therapeutic strategies are focusing on modulating the p53-p21 axis to restore cell cycle control. Concurrently, the selective elimination of p21-high senescent cells is being actively pursued to treat age-related degenerative diseases, shifting the R&D focus from broad-spectrum cytostatic agents to highly targeted molecular degraders (PROTACs) and gene therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Activators / Inhibitors | Unity Biotechnology, Cleara Biotech | Osteoarthritis, Ophthalmic Diseases, Fibrosis | Target engagement and binding assays (Need high-purity recombinant CDKN1A proteins) |
| PROTACs / Molecular Glues | Arvinas, Kymera Therapeutics | Refractory Solid Tumors, Hematological Malignancies | Protein degradation kinetics (Need high-titer Lentivirus for stable reporter line generation) |
| Gene Therapy / mRNA | Moderna, AstraZeneca | Cardiovascular Diseases, Restenosis | Overexpression validation and functional rescue (Need sequence-verified CDKN1A Promise-ORF) |